Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WRN | Q14191 | 1/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31713647 | 0.88 | WRN (0.48) | WRNKDM4EAKR1B1MAPTTP53 | |
| SCHEMBL31713832 | 0.87 | WRN (0.49) | WRNGPBAR1KDM4EAKR1B1MAPT | |
| SCHEMBL31713805 | 0.86 | WRN (0.51) | WRNGPBAR1KDM4EAKR1B1MAPT | |
| SCHEMBL31713897 | 0.85 | WRN (0.47) | WRNKDM4EAKR1B1MAPTTP53 | |
| SCHEMBL31713896 | 0.85 | WRN (0.47) | WRNKDM4EAKR1B1MAPTTP53 | |
| SCHEMBL31713682 | 0.85 | WRN (0.47) | WRNKDM4EAKR1B1MAPT | |
| SCHEMBL31713369 | 0.85 | WRN (0.51) | WRNGPBAR1KDM4EMAPTLMNA | |
| SCHEMBL31713776 | 0.84 | WRN (0.47) | WRNKDM4EMAPTLMNA | |
| SCHEMBL31713751 | 0.83 | WRN (0.47) | WRNGPBAR1KDM4EAKR1B1MAPT | |
| SCHEMBL31713758 | 0.83 | WRN (0.50) | WRNGPBAR1KDM4EMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333419-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | INCYTE CORPORATION (US) | 2025-10-30 | — | — | US | claimed |
| US-20250333419-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | INCYTE CORPORATION (US) | 2025-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333419-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | WRN, BLM, RECQL | WRN 1/4885GPBAR1 3335/4885KDM4E 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.